Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study

Launched by HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST · Mar 17, 2025

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males and females aged ≥18 years.
• • Able to give informed consent
• • Serum ferritin \<700ug/L
• • Transferrin saturation level \<40%
• • No intravenous iron for last 4 weeks before randomisation (patients may be pre-identified and included after 4-week washout period)
• • Received maintenance peritoneal dialysis therapy for at least 4 weeks
• • Expected to remain on peritoneal dialysis therapy for duration of study
• Exclusion Criteria:
• • Inadequate dialysis deemed by responsible clinician
• • Probability of need for transfusion within 1 week of enrolment
• • Anticipated major surgery that the responsible clinician feels will impact response to treatment
• • Haemochromatosis / haemosiderosis or ALT \>x3 normal
• • Are deemed to be most suited to best-supportive or end-of-life care at time of screening
• • Women of childbearing potential not using effective means of contraception
• • Have been involved in another medicinal study (CTIMP) within past 4 weeks
• • Known allergy or adverse reaction to oral or intravenous iron preparations
• • CRP \>50, TSATs \>40%, SF \>700 at time of recruitment
• • Active infection, HIV, active Hep B or C
• • Are unable or unwilling to consent to or complete the study procedures